Dosing Challenges and Benefits of Vericiguat in a Patient With Decompensated Heart Failure: A Case Report

Vericiguat has emerged as a promising add-on therapy for decompensated heart failure with reduced ejection fraction (HFrEF) patients requiring hospitalization or IV diuretic administration. In the VICTORIA trial (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction),...

Descripción completa

Detalles Bibliográficos
Autores principales: Speranza-Sánchez, Mario, Zavaleta, Esteban, Sancho-Zumbado, Sonia, Elizondo-Urrutia, Juan Carlos, Quirós-Romero, Alonso, Chaverri-Fernández, José, García-Montero, Jonathan, Arguedas-Chacón, Sebastián
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Cardiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689053/
https://www.ncbi.nlm.nih.gov/pubmed/38046500
http://dx.doi.org/10.7759/cureus.48065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689053/
https://www.ncbi.nlm.nih.gov/pubmed/38046500
http://dx.doi.org/10.7759/cureus.48065

Ejemplares similares